Ampyra Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Ampyra Indications
Indications
Ampyra Dosage and Administration
Adult
Children
Renal Impairment
Clearance of dalfampridine is decreased in patients with renal impairment and is significantly correlated with creatinine clearance. Estimated CrCl should be calculated prior to starting treatment. Mild impairment may result in an increased risk of seizures as dalfampridine plasma levels in these patients may approach those seen at a dose of 15mg twice daily. Treatment is contraindicated in moderate to severe impairment.
Ampyra Contraindications
Contraindications
Ampyra Boxed Warnings
Not Applicable
Ampyra Warnings/Precautions
Warnings/Precautions
Ampyra Pharmacokinetics
Absorption
Rapidly and completely absorbed from the gastrointestinal tract. Single Ampyra tablet 10mg doses administered to individuals in a fasted state gave peak concentrations ranging from 17.3ng/mL to 21.6ng/mL occurring 3 to 4 hours post administration (Tmax).
Distribution
Dalfampridine is largely unbound to plasma proteins (97–99%).
Elimination
Dalfampridine and metabolites elimination is nearly complete after 24 hours, with 95.9% of the dose recovered in urine and 0.5% recovered in feces. Elimination half-life of dalfampridine is 5.2 to 6.5 hours.
Ampyra Interactions
Interactions
Ampyra Adverse Reactions
Adverse Reactions
Ampyra Clinical Trials
Ampyra Note
Not Applicable
Ampyra Patient Counseling
Cost Savings Program
Images
